QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price & News

$18.50
-0.20 (-1.07%)
(As of 04:23 PM ET)
Compare
Today's Range
$17.83
$18.66
50-Day Range
$18.08
$23.45
52-Week Range
$17.80
$41.93
Volume
2.07 million shs
Average Volume
1.03 million shs
Market Capitalization
$1.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.40

Amylyx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
166.2% Upside
$49.40 Price Target
Short Interest
Bearish
19.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
164.66%
From $1.16 to $3.07 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

150th out of 975 stocks

Pharmaceutical Preparations Industry

53rd out of 456 stocks


AMLX stock logo

About Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

AMLX Price History

AMLX Stock News Headlines

Amylyx Pharmaceuticals: A High Risk/High Reward Stock
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
AMLX - Amylyx Pharmaceuticals, Inc.
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Q2 2023 Amylyx Pharmaceuticals Inc Earnings Call
Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from Mizuho Securities
Amylyx Stock Has A Good Entry Point, Says Bullish Goldman Sachs
Why Shares of Amylyx Pharmaceuticals Were Up Monday
See More Headlines
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Company Calendar

Last Earnings
8/10/2023
Today
9/28/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMLX
Fax
N/A
Employees
338
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.40
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+167.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-198,380,000.00
Pretax Margin
-36.79%

Debt

Sales & Book Value

Annual Sales
$22.23 million
Book Value
$5.14 per share

Miscellaneous

Free Float
59,427,000
Market Cap
$1.25 billion
Optionable
Not Optionable
Beta
-0.93
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Joshua B. Cohen (Age 31)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. Justin B. Klee (Age 32)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. James M. Frates M.B.A. (Age 56)
    Chief Financial Officer
    Comp: $695.12k
  • Ms. Gina M. Mazzariello (Age 52)
    Chief Legal Officer & Gen. Counsel
    Comp: $794.83k
  • Mr. Tom Holmes
    Chief Technical Operations Officer
  • Lindsey Allen
    Head of Investor Relations & Communications
  • Ms. Shauna Horvath
    Head of Global Marketing
  • Ms. Debra L. Canner (Age 64)
    Global Head of HR & CHRO
  • Ms. Margaret M. Olinger M.B.A (Age 58)
    Global Head of Commercial & Chief Commercial Officer
  • Dr. Patrick D. Yeramian M.D. (Age 64)
    MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer













AMLX Stock - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMLX shares.
View AMLX analyst ratings
or view top-rated stocks.

What is Amylyx Pharmaceuticals' stock price forecast for 2023?

5 equities research analysts have issued 1 year price objectives for Amylyx Pharmaceuticals' stock. Their AMLX share price forecasts range from $48.00 to $50.00. On average, they anticipate the company's share price to reach $49.40 in the next year. This suggests a possible upside of 167.0% from the stock's current price.
View analysts price targets for AMLX
or view top-rated stocks among Wall Street analysts.

How have AMLX shares performed in 2023?

Amylyx Pharmaceuticals' stock was trading at $36.95 at the beginning of the year. Since then, AMLX shares have decreased by 49.9% and is now trading at $18.50.
View the best growth stocks for 2023 here
.

When is Amylyx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our AMLX earnings forecast
.

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced its quarterly earnings data on Thursday, August, 10th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.30. The firm had revenue of $98.22 million for the quarter, compared to analysts' expectations of $84.30 million. Amylyx Pharmaceuticals had a negative trailing twelve-month return on equity of 23.80% and a negative net margin of 37.95%.

When did Amylyx Pharmaceuticals IPO?

(AMLX) raised $190 million in an IPO on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.

What is Amylyx Pharmaceuticals' stock symbol?

Amylyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLX."

Who are Amylyx Pharmaceuticals' major shareholders?

Amylyx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (7.23%), BlackRock Inc. (5.22%), Marshall Wace LLP (2.94%), Rock Springs Capital Management LP (2.29%), Goldman Sachs Group Inc. (2.00%) and State Street Corp (1.72%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian.
View institutional ownership trends
.

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amylyx Pharmaceuticals' stock price today?

One share of AMLX stock can currently be purchased for approximately $18.50.

How much money does Amylyx Pharmaceuticals make?

Amylyx Pharmaceuticals (NASDAQ:AMLX) has a market capitalization of $1.25 billion and generates $22.23 million in revenue each year. The company earns $-198,380,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.

How many employees does Amylyx Pharmaceuticals have?

The company employs 338 workers across the globe.

How can I contact Amylyx Pharmaceuticals?

The official website for the company is amylyx.com. The company can be reached via phone at 617-682-0917 or via email at investors@amylyx.com.

This page (NASDAQ:AMLX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -